Helius Medical Technologies shares are trading lower. The company announced preliminary results from its Therapeutic Experience Program open-label observational study which evaluates the impact of subjects' adherence to the Portable Neuromodulation Stimulator Therapy program that treat gait deficit due to multiple sclerosis.
Portfolio Pulse from Benzinga Newsdesk
Helius Medical Technologies shares are declining following the release of preliminary results from their Therapeutic Experience Program study. The study evaluates the impact of adherence to their Portable Neuromodulation Stimulator Therapy for treating gait deficit in multiple sclerosis patients.
September 30, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Helius Medical Technologies shares are trading lower after announcing preliminary results from their study on the Portable Neuromodulation Stimulator Therapy for multiple sclerosis. The market may be reacting to the results or the nature of the study.
The decline in Helius Medical Technologies' stock price is likely due to the market's reaction to the preliminary results of their study. Investors may be concerned about the effectiveness or commercial viability of the therapy based on these results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100